A research team from Oxford University and the University of Birmingham were able to come up with a groundbreaking development that could massively further cancer treatments. According to SciTechDaily, this development involves the creation of the world's first "organoids" of human bone marrow which accurately captures vital features of real human bone marrow.
The said technology is the focus of a certain patent application pushed forward by the University of Birmingham Enterprise. It enables the assessing of several anti-cancer drugs and the examination of individualized therapies for respective cancer patients.
First Human Bone Marrow "Organoids"
The study was added to the Cancer Discovery journal.
According to SciTechDaily, the developed organoids largely mirror the architectural, cellular, and molecular characteristics of bone marrow that is myelopoietic or blood cell-building.
Oxford University notes how such organoids also have the capacity to sustain life of blood cancer cells within the lab. Such a feat was extremely difficult to execute in the past. This implies that clinicians could test patient-specific treatments and look for treatments that could most likely handle the cancer.
Dr. Abdullah Khan, study first author and a Sir Henry Wellcome Fellow from the Institute of Cardiovascular Science at the University of Birmingham, expressed how the researchers remarkably discovered how the organoid cells mirror actual bone marrow cells not just when it came to function and activity but also in the architectural aspects. Such types of cells arrange and organize themselves inside the organoid, the same way that they do in real human bone marrow.
Such cell types were generated using a recent method that involves human stem cells that are raised in an intricately developed 3D scaffold. This was done to come up with the vital cell types present within human bone marrow.
The architecture allowed the team to dig deeper into the interaction of bone marrow when it comes to regular blood cell production. They were also able to examine the disbursement procedures within the myelofibrosis or bone marrow fibrosis. Such fibrosis may appear among patients with particular blood cancers and it is still incurable.
Implications for Cancer Treatment
Professor Bethan Psaila, senior author of the study and hematology doctor as well as Radcliffe Department of Medicine research group leader, expresses how when it comes to the proper understanding of the process and reason behind the development of blood cancer, it is necessary to try out experiments that largely mimic actual human bone marrow. Professor Psaila notes the excitement that comes with such a recent system as it enables the studying of cancer cells directly taken from patients, rather than having to rely on animal bases or other systems.
Dr. Khan also notes how such findings are a major step. They facilitate insight regarding cancel cell growth patterns and potentially enable a treatment approach with a greater element of personalization. Such a platform can be used to examine drugs on the grounds of personalized medicine.
The development and validation of such a model is the first vital step. In the ongoing project, the researchers will be collaborating with others to understand the bone marrow's function even more among those who are healthy and to know how things go wrong when people get blood illnesses.
Dr. Psaila also mentions their hopes for such a new method to aid in the acceleration of examining novel blood cancer therapies.
RELATED ARTICLE : Human Brain Organoids Grown in Rats to Study Neurological Diseases
Check out more news and information on Medicine and Health in Science Times.
